Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with...

Descripción completa

Detalles Bibliográficos
Autor principal: Park, Jung Gil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612290/
https://www.ncbi.nlm.nih.gov/pubmed/26527250
http://dx.doi.org/10.3350/cmh.2015.21.3.287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612290/
https://www.ncbi.nlm.nih.gov/pubmed/26527250
http://dx.doi.org/10.3350/cmh.2015.21.3.287

Ejemplares similares